Core Viewpoint - The performance of innovative drug ETFs in the A-share market has been strong, with significant increases in trading volume and price, indicating growing investor interest in the sector [1][3]. Group 1: ETF Performance - The Tianhong Innovative Drug ETF (517380) saw a half-day increase of 2.11%, with a trading volume of approximately 13.31 million yuan and a total size of 778 million units [3][6]. - Other innovative drug ETFs also performed well, with the Huatai-PB Innovative Drug ETF (517120) increasing by 1.99% and the Innovative Drug 50 ETF (159835) rising by 1.88% [2][6]. - The overall trading activity in the innovative drug ETFs was robust, with the Innovative Drug ETF (159992) achieving a half-day trading amount of nearly 300 million yuan [1][9]. Group 2: Index Tracking - The Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index tracks 50 stocks listed in Shanghai, Shenzhen, or Hong Kong that have high R&D investment and strong momentum [4][6]. - The index aims to reflect the performance of the most representative stocks in the innovative drug industry, selected based on market capitalization [4][9]. - The China Securities Hong Kong-Shenzhen Innovative Drug Industry Index includes stocks from A-shares and eligible Hong Kong stocks, focusing on companies involved in innovative drug R&D and production [6][9]. Group 3: Major Holdings - Major stocks in the Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index include Baijie Shenzhou (6160.HK) with a weight of 12.00%, WuXi AppTec (603259.SH) at 11.26%, and Hengrui Medicine (600276.SH) at 8.39% [5][10]. - The China Securities Innovative Drug Industry Index also features significant holdings such as WuXi AppTec (603259) with a weight of 12.58% and Hengrui Medicine (600276) at 9.51% [10].

恒瑞医药A股涨停，封单超30万手，创21年7月以来新高，H股现涨17.4%。 ...

【导读】 A 股午前突发跳水，上纬新材新晋 "10 倍股 " 中国基金报记者 晨曦 大家好！来一起关注上午的市场行情和最新资讯 ~ 7 月 28 日上午， A 股震荡走高，午前忽然跳水。截至午间收盘，上证指数跌 0.17% ，深 证成指跌 0.16% ，创业板指涨 0.1% 。 全市场半日成交额为 1.14 万亿元，较上日略有放量；全市场 3057 只个股下跌， 2162 只 个股上涨。 盘面上，上午金融、制药、航天军工、通信设备等板块走强， PEEK 材料、稀土、稳定币等 概念股持续活跃；煤炭、航运板块集体调整，钢铁、贵金属、光伏玻璃等回调。 | 多元金融 1.01% | 发电设备 0.76% | 通信设备 0.68% | 券商 0.38% | | --- | --- | --- | --- | | 包装 0.37% | 商业服务 0.25% | 陆路运输 -1.29% | 航空 -1.32% | | 石油天然气 -1.33% | 贵金属 -1.55% | 互联网 -1.57% | 钢铁 -1.71% | | 日用化工 -1.91% | 海运 -1.93% | 软饮料 -2.39% | 煤炭 -2.79% ...

Market Overview - The Hang Seng Index (HSI) closed up 0.40% at 25,490.45 points, while the Tech Index (KSI) fell 0.59% to 5,644.52 points [1] - The total market turnover reached HKD 149.725 billion [1] Sector Performance - Major financial sectors, including Chinese brokerage firms and insurance, saw significant gains, while coal and non-ferrous metals sectors experienced declines [1] Notable Stocks - China Tobacco Hong Kong rose by 13.78% after reaching an agreement with China National Tobacco on maintaining its duty-free cigarette business in mainland China [1] - Ping An Insurance (601318) increased by 3.21% [1] - Hengrui Medicine (600276) surged by 15.43% [1] - China Shenhua Energy (601088) decreased by 1.85% [1]

Core Viewpoint - Heng Rui Medicine's stock surged over 10% following the announcement of a significant overseas licensing deal with GSK, marking a key step in the company's international expansion strategy [1][2] Group 1: Financial Details - The agreement with GSK involves the global exclusive rights to the innovative drug HRS-9821 and up to 11 additional research projects, excluding mainland China and Hong Kong/Macau, with an upfront payment of $500 million [1] - The potential total revenue for Heng Rui could reach approximately $12 billion if all project options are exercised and milestones are achieved, along with tiered royalties on overseas sales [1] - Since 2018, Heng Rui has completed 14 licensing deals involving 17 molecular entities, with a total potential transaction value of about $14 billion and upfront payments exceeding $600 million [2] Group 2: Strategic Implications - The collaboration with GSK is seen as a validation of Heng Rui's innovative drug development capabilities and enhances its brand influence and overseas performance [1][2] - Heng Rui's product matrix includes a strong focus on oncology, with 10 marketed products, 4 under review, and several in development, particularly highlighting the HER2 ADC drug SHR-A1811, which has received 8 breakthrough therapy designations [1] - The dual strategy of "independent innovation + overseas licensing" is accelerating Heng Rui's integration into the global innovative drug industry chain [2]

Market Overview - The FTSE China A50 Index showed mixed performance among bank stocks, while oil, coal, and electric power stocks declined [1][6] Banking Sector - Everbright Bank had a market capitalization of 242.84 billion with a trading volume of 0.38 billion, closing at 4.11, up by 0.03 (0.74%) [3] Insurance Sector - China Life Insurance had a market capitalization of 382.10 billion, with a trading volume of 1.46 billion, closing at 59.62, up by 1.12 (2.99%) [3] - China Pacific Insurance had a market capitalization of 371.44 billion, with a trading volume of 1.02 billion, closing at 38.61, up by 1.54 (2.65%) [3] - Ping An Insurance had a market capitalization of 1,085.69 billion, with a trading volume of 5.02 billion, closing at 8.64, up by 0.17 (2.01%) [3] Alcohol Industry - Kweichow Moutai had a market capitalization of 1,806.43 billion, with a trading volume of 3.41 billion, closing at 122.78, down by 16.99 (-1.17%) [3] - Shanxi Fenjiu had a market capitalization of 221.85 billion, with a trading volume of 1.14 billion, closing at 1438.01, down by 3.73 (-2.01%) [3] - Wuliangye had a market capitalization of 476.58 billion, with a trading volume of 1.31 billion, closing at 181.85, down by 0.76 (-0.62%) [3] Technology Sector - Haiguang Information had a market capitalization of 246.59 billion, with a trading volume of 1.20 billion, closing at 341.73, down by 0.23 (-0.07%) [3] - Northern Huachuang had a market capitalization of 282.22 billion, with a trading volume of 4.45 billion, closing at 674.60, up by 1.30 (0.19%) [3] - Cambricon Technologies had a market capitalization of 32.38 billion, with a trading volume of 1.79 billion, closing at 139.31, down by 2.18 (-1.54%) [3] Energy Sector - Sinopec had a market capitalization of 269.58 billion, with a trading volume of 5.34 billion, closing at 5.88, down by 0.11 (-1.27%) [3] - PetroChina had a market capitalization of 1,566.66 billion, with a trading volume of 8.05 billion, closing at 8.56, down by 0.06 (-1.08%) [3] Automotive Sector - BYD had a market capitalization of 1,846.26 billion, with a trading volume of 5.87 billion, closing at 37.78, down by 0.47 (-2.26%) [3] Securities Sector - CITIC Securities had a market capitalization of 363.53 billion, with a trading volume of 32.66 billion, closing at 29.86, up by 0.41 (2.03%) [4] Consumer Electronics - Luxshare Precision had a market capitalization of 272.89 billion, with a trading volume of 23.13 billion, closing at 28.83, up by 0.17 (0.59%) [4] Home Appliances - Gree Electric had a market capitalization of 228.16 billion, with a trading volume of 10.44 billion, closing at 25.72, down by 0.09 (-0.19%) [4] Pharmaceutical Sector - Heng Rui Medicine had a market capitalization of 404.93 billion, with a trading volume of 4.53 billion, closing at 48.52, up by 4.61 (8.17%) [4]

Core Viewpoint - Heng Rui Medicine has entered into an agreement with GSK, involving an upfront payment of $500 million and potential milestone payments of up to $12 billion, leading to a significant surge in its stock price [2][4]. Financial Terms - GSK will pay Heng Rui an upfront fee of $500 million, with potential total milestone payments reaching approximately $12 billion if all projects are exercised and milestones achieved [7]. - Heng Rui will also be entitled to receive a tiered sales commission from GSK, excluding regions in mainland China and Hong Kong, Macau, and Taiwan [7]. Project Details - The HRS-9821 project is a potential best-in-class PDE3/4 inhibitor currently in clinical development for chronic obstructive pulmonary disease (COPD) [4]. - The agreement includes exclusive licensing rights for up to 11 additional projects in various therapeutic areas, including oncology, respiratory, autoimmune, and inflammatory diseases, which are currently in non-clinical research stages [4][5]. Strategic Implications - The agreement is expected to broaden the overseas market for HRS-9821 and other innovative products, enhancing the company's brand and overseas performance [8]. - Since 2018, Heng Rui has engaged in 13 licensing transactions with global partners, involving 16 molecular entities and a potential total transaction value of approximately $14 billion, with an upfront payment total of around $600 million [8]. - The company's internationalization process is anticipated to accelerate, especially with recent leadership changes and a robust pipeline of over 90 innovative products in clinical development [8].

Group 1 - The innovative drug sector in Hong Kong and A-shares continues to strengthen, with notable gains in stocks such as MicroPort Medical, China Biologic Products, and Innovent Biologics [1] - On July 28, 2025, Hengrui Medicine announced an agreement with GSK, granting GSK exclusive global rights to the HRS-9821 project and up to 11 other projects, with an upfront payment of $500 million and potential milestone payments totaling approximately $12 billion [1] - Haitong International highlights the sustained high prosperity in the innovative drug sector, with Pharma companies expected to undergo a revaluation, while Biopharma/Biotech companies show strong growth potential as their innovative pipelines begin to yield results [1] Group 2 - The Hang Seng Biotechnology ETF (159615) closely tracks the Hang Seng Biotechnology Index, which reflects the overall performance of the largest 50 biotechnology companies listed in Hong Kong [2] - The top ten weighted stocks in the Hang Seng Biotechnology Index include Innovent Biologics, WuXi Biologics, BeiGene, and others [2] - The Southern Innovative Drug ETF (159858) tracks the CSI Innovative Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development [2]

【导读】恒瑞医药与 GSK 达成协议，首付款为 5 亿美元，里程碑付款或达 120 亿美元，股 价暴涨 中国基金报记者 卢鸰 恒瑞医药又有大动作。 恒瑞医药 7 月 28 日早间公告，与知名跨国药企 GSK 达成协议，将 HRS-9821 项目的全球 独家权利和至多 11 个项目的全球独家许可的独家选择权有偿许可给 GSK， 首付款为 5 亿 美元，里程碑付款或达 120 亿美元。 里程碑付款或达 120 亿美元 HRS-9821 是一款潜在的同类最佳 PDE3/4 抑制剂，目前正处于临床开发阶段，可用于治疗 慢性阻塞性肺病（ COPD ）。其他 11 个项目涉及肿瘤、呼吸、自免和炎症等多个治疗领域 的创新药物，目前均处于非临床研究阶段。 根据协议，恒瑞将主导这些项目的研发，最晚至完成包括海外受试者数据的 Ⅰ 期临床试验。 GSK 将拥有在最晚至 Ⅰ 期临床完成时，行使全球（不包括中国大陆、港澳台）进一步开发 和商业化每个项目的独家选择权，以及某些项目替换权。 财务条款方面， GSK 将向恒瑞支付 5 亿美元的首付款；如果所有项目均获得行使选择权且 所有里程碑均已实现，恒瑞将有资格获得未来基于成功开发、注册和 ...

Hengrui Pharmaceuticals shares rallied to their highest levels in four years after GSK agreed to pay $500 million upfront for the company’s potential chronic lung disease treatment https://t.co/URYGr1Pps7 ...